Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 8/20 | 0.64 |
| ▸ | AKT1 | P31749 | 1/20 | 0.41 |
| ▸ | PSMD14 | O00487 | 2/20 | 0.40 |
| ▸ | PRNP | P04156 | 2/20 | 0.39 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15720413 | 0.84 | TRPA1 (0.66) | TRPA1PSMD14PRNP | |
| SCHEMBL15720498 | 0.81 | TRPA1 (0.64) | TRPA1PSMD14PRNPSLC2A1 | |
| SCHEMBL15720399 | 0.78 | TRPA1 (1.00) | TRPA1AKT1 | |
| SCHEMBL15720555 | 0.66 | TRPA1 (0.64) | TRPA1PSMD14PRNPSLC2A1 | |
| SCHEMBL15720415 | 0.63 | TRPA1 (1.00) | TRPA1PRNP | |
| SCHEMBL1691717 | 0.62 | TSPO (0.52) | — | |
| SCHEMBL15720499 | 0.61 | TRPA1 (1.00) | TRPA1 | |
| SCHEMBL5222434 | 0.60 | SLC6A2 (0.59) | — | |
| SCHEMBL12495322 | 0.60 | RORB (0.53) | — | |
| SCHEMBL1692150 | 0.59 | TSPO (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9394304-B2 | Imidazopyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2016-07-19 | — | — | US | claimed |
| EP-2920169-A1 | IMIDAZOPYRIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2015-09-23 | — | — | EP | claimed |
| US-20150246918-A1 | IMIDAZOPYRIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2015-09-03 | — | — | US | claimed |
| WO-2014076021-A1 | IMIDAZOPYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-05-22 | — | — | WO | claimed |
| US-9394304-B2 | Imidazopyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2016-07-19 | — | — | US | disclosed |
| EP-2920169-A1 | IMIDAZOPYRIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2015-09-23 | — | — | EP | disclosed |
| US-20150246918-A1 | IMIDAZOPYRIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2015-09-03 | — | — | US | disclosed |
| WO-2014076021-A1 | IMIDAZOPYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150246918-A1 | IMIDAZOPYRIDINE DERIVATIVES | QDPR, ADRB3, HRH4 | TRPA1 882/4885AKT1 3993/4885PSMD14 2224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.